While the Food and Drug Administration (FDA) identified a link between gadolinium-based contrast agents and nephrogenic systemic fibrosis, the FDA has taken very few actions to prevent the use of the contrast agent in MRI scans. 

Because these contrast agents are still used in some MRI scans, it is important to be able to identify when gadolinium-based contrast agents are used in MRIs. The five most common types of these contrast agents are Magnevist, MultiHance, Omniscan, OptiMARK, and Prohance.

If you have received an MRI with a gadolinium-based contrast agent, contact the NSF and NSD lawyers of Williams Kherkher at 800-761-3187.